TP53 Co-Mutations and Prognosis in EGFR-Mutated NSCLC

August 20, 2026

This segment examines how often TP53 co-mutations occur alongside EGFR and what their presence should change. TP53 is described as common in EGFR-mutated advanced non-small cell lung cancer, consistent with published estimates, and among the most frequently encountered co-alterations. It is treated as more than an incidental finding, given shorter progression-free and overall survival and concern that treatment works less well, and functions as a risk-stratification tool when weighing osimertinib monotherapy against intensification with chemotherapy or a lazertinib-containing regimen. The discussion notes heterogeneity within TP53 itself, including DNA-binding-domain and gain-of-function mutations and co-mutations in RB1, NF1, BRCA1, and PTEN. TP53 is positioned as independent of other poor prognostic features such as brain metastases, liver metastases, and baseline circulating tumor DNA, with several appearing together supporting a more aggressive combination approach upfront.